Noxilizer Achieves Key Milestones in Commercialization of Proprietary Sterilization Technology, November 15, 2012

Catheter Research Inc. of Indianapolis orders first Noxilizer RTS 360 Industrial NO2 Sterilizer to provide contract sterilization services to global medical device companies

(Baltimore, MD--November 15, 2012) Noxilizer Inc. announced today that Catheter Research Inc. (CRI) (www.catheterresearch.com) based in Indianapolis, IN has ordered the RTS 360 Industrial NO2 Sterilizer. CRI is a contract medical device manufacturer with customers who include global leaders in the industry. In addition to sterilizing their own devices, CRI will offer sterilization services to medical device companies located in the Midwest. The RTS 360 will be installed in January 2013.

Noxilizer’s proprietary low temperature sterilization technology is the first innovation in the industry in over 20 years. The advantages over existing modes of sterilization are: room temperature process, fast cycle time and improved worker safety over existing methods. The system allows for inventory release in hours versus weeks and cost savings of 40% to 60% for medical devices companies. Noxilizer sells the RTS 360 Industrial NO2Sterilizer directly to companies so that they can bring sterilization in house, as well as provides contract sterilization services.

This marks one of several important milestones that Noxilizer has recently achieved. Other accomplishments include:

  • http://noxilizer.com/images/pic-global-bullet-default.png); background-color: transparent; list-style-type: none; background-position: 0px 8px; background-repeat: no-repeat no-repeat; ">Raised $3.5M and closed the Series B financing round. Investors included The Abell Foundation (www.abell.org) in Baltimore, MD. The success of the round was enhanced by investor participation in the Maryland Biotechnology Investment Tax Credit Program.
  • http://noxilizer.com/images/pic-global-bullet-default.png); background-color: transparent; list-style-type: none; background-position: 0px 8px; background-repeat: no-repeat no-repeat; ">Featured cover story on Noxilizer’s technology in a prominent industry publication, Medical Design Briefs (September); and
  • http://noxilizer.com/images/pic-global-bullet-default.png); background-color: transparent; list-style-type: none; background-position: 0px 8px; background-repeat: no-repeat no-repeat; ">Committed to move to the University of Maryland BioPark (www.umbiopark.com) in early 2013 to accommodate increasing staff, lab and manufacturing space.

“Noxilizer has entered the commercialization phase. Along with the contract sterilization services we provide in our Baltimore facility, the commitment of CRI and other prospective customers, Noxilizer is building a revenue stream, a strong foundation of growth and increased value for our shareholders,” says Lawrence Bruder, President & CEO.

About Noxilizer, Inc.:
Noxilizer has a unique and superior NO2-based sterilization technology that is revolutionizing two major sterilization markets — medical device/pharmaceutical/biotechnology manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for next generation medical devices, prefilled syringes and drug/device combination products. Noxilizer also sells the RTS 360 Industrial NO2 Sterilizer to companies that want to sterilize their own products. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment used in minimally-invasive surgical procedures. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD. For more information about Noxilizer, please visit: www.noxilizer.com.